507 related articles for article (PubMed ID: 10462204)
1. A new human prostate carcinoma cell line, 22Rv1.
Sramkoski RM; Pretlow TG; Giaconia JM; Pretlow TP; Schwartz S; Sy MS; Marengo SR; Rhim JS; Zhang D; Jacobberger JW
In Vitro Cell Dev Biol Anim; 1999; 35(7):403-9. PubMed ID: 10462204
[TBL] [Abstract][Full Text] [Related]
2. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors.
Kochera M; Depinet TW; Pretlow TP; Giaconia JM; Edgehouse NL; Pretlow TG; Schwartz S
Prostate; 1999 Sep; 41(1):7-11. PubMed ID: 10440870
[TBL] [Abstract][Full Text] [Related]
3. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma.
Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE
Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
[TBL] [Abstract][Full Text] [Related]
7. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Chen CT; Gan Y; Au JL; Wientjes MG
Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
[TBL] [Abstract][Full Text] [Related]
8. Androgen-repressed phenotype in human prostate cancer.
Zhau HY; Chang SM; Chen BQ; Wang Y; Zhang H; Kao C; Sang QA; Pathak SJ; Chung LW
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15152-7. PubMed ID: 8986779
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS
Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
[TBL] [Abstract][Full Text] [Related]
11. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
13. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells.
Gery S; Sawyers CL; Agus DB; Said JW; Koeffler HP
Oncogene; 2002 Jul; 21(31):4739-46. PubMed ID: 12101412
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate.
Danielpour D; Kadomatsu K; Anzano MA; Smith JM; Sporn MB
Cancer Res; 1994 Jul; 54(13):3413-21. PubMed ID: 8012960
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression.
Bae VL; Jackson-Cook CK; Brothman AR; Maygarden SJ; Ware JL
Int J Cancer; 1994 Sep; 58(5):721-9. PubMed ID: 8077059
[TBL] [Abstract][Full Text] [Related]
16. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.
Webber MM; Quader ST; Kleinman HK; Bello-DeOcampo D; Storto PD; Bice G; DeMendonca-Calaca W; Williams DE
Prostate; 2001 Apr; 47(1):1-13. PubMed ID: 11304724
[TBL] [Abstract][Full Text] [Related]
17. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
[TBL] [Abstract][Full Text] [Related]
18. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
Wainstein MA; He F; Robinson D; Kung HJ; Schwartz S; Giaconia JM; Edgehouse NL; Pretlow TP; Bodner DR; Kursh ED
Cancer Res; 1994 Dec; 54(23):6049-52. PubMed ID: 7525052
[TBL] [Abstract][Full Text] [Related]
19. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells.
Gerdes MJ; Dang TD; Larsen M; Rowley DR
Endocrinology; 1998 Aug; 139(8):3569-77. PubMed ID: 9681509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
